ATS 2020 Advance Program

hypertension The secondary professional audiences are basic, translational and clinical scientists Objectives At the conclusion of this session, the participant will be able to: • define new strategies to identify already existing drugs that could be used in the treatment of cardiopulmonary disease; • learn new ways to apply machine learning and artificial intelligence in the practice of managing cardiopulmonary disease; • familiarize novel therapeutic agents for PAH that are in early phase 2 and phase 3 clinical trials. PAH continues to remain a fatal disease with a median survival of 5-7 years. Currently there are 13 FDA approved PAH-specific therapies for the management of PAH. They increase exercise capacity modestly and reduce hospital admission, but are expensive and not curative. Since 2005, no new therapeutic pathways have been identified for the treatment of PAH. There is a clear unmet need for novel treatments for PAH that iimprove long-term outcomes. Advances in computational and systems biology coupled with the rapidly growing data from electronic health records as well as human molecular profiling provides opportunities to leverage big data and repurpose existing drugs for novel clinical purposes to promote cardiopulmonary health. This session intends to explore the current state of the art methods and ongoing challenges to utilize network biology, machine learning, and artificial intelligence for defining novel uses for existing drugs, the experimental platforms needed for those predictions, and the clinical ramifications for incorporating these processes in translational practice. In addition, this session will highlight novel therapies that are in phase 2 clinical trials for the treatment of PAH. Chairing: V.V. McLaughlin, MD, Ann Arbor, MI E.F. Spiekerkoetter, MD, Palo Alto, CA 9:15 A Patient's Perspective Speaker To Be Announced 9:20 Systems and Network Strategies for Drug Repurposing J. Loscalzo, MD, PhD, Boston, MA 9:39 Rituximab for Scleroderma-Associated PAH: Hype or Hope? R.T. Zamanian, MD, Stanford, CA 9:58 Computational Drug Repurposing of Chemotherapeutics in Pulmonary Hypertension S.Y. Chan, MD, PhD, Pittsburgh, PA 10:17 IL-1 Blockade in Pulmonary Arterial Hypertension and Right Ventricular Failure D.C. Grinnan, MD, Richmond, VA 10:36 Drug Discovery Using Artificial Intelligence Engines: Challenges and Opportunities K. Rhee, MD, MPP, Boston, MA 10:55 Sotatercept for Treatment of PAH P.B. Yu, MD, PhD, Boston, MA CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM A8 PRECISION MEDICINE IN PEDIATRIC RESPIRATORY DISEASES: READY FOR PRIME TIME? Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems; Section on Genetics and Genomics 9:15 a.m. - 11:15 a.m. Target Audience Pediatricians and pulmonary specialists taking care of children with chronic lung disease. Translational and clinical scientists whose research focuses on improving the management of children and adolescents with respiratory disorders. Objectives At the conclusion of this session, the participant will be able to: • review the current state of research towards precision and gene-based medicine in different diseases that affect respiratory health in children and adolescents; • understand the evidence supporting the clinical use of precision medicine approaches in pediatric lung diseases; ATS 2020 • Philadelphia, PA 40 SUNDAY • MAY 17